The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
Yingmiao Liu
No relevant relationships to disclose
Jeffrey Melson Clarke
No relevant relationships to disclose
Mark D. Starr
No relevant relationships to disclose
John C. Brady
No relevant relationships to disclose
Herbert Pang
No relevant relationships to disclose
Christel Rushing
No relevant relationships to disclose
Delia Alvarez
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Herbert Hurwitz
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Lilly; Roche; Sanofi
Research Funding - Amgen; Genentech; GlaxoSmithKline; Pfizer; Roche; Sanofi
Andrew B. Nixon
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - Amgen; Genentech; TRACON Pharma